V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004355 | 10006629 | 1.7 | 76 | Palliative (P) | null | 2016-07-28 | Irinotecan + Modified De Gramont | null | null | 10520115 | IRINOTECAN + MDG |
| 10004356 | 10006629 | 1.6 | 73.2 | Curative (C) | 2017-10-08 | 2017-10-09 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | 10520115 | ABIRATERONE |
| 10004357 | 10002753 | null | 68 | Adjuvant (A) | null | 2017-07-24 | FLUOROURACIL + FOLINIC ACID | N | N | 10520401 | FLUOROURACIL |
| 10004358 | 10002753 | 1.82 | 123 | Disease modification (D) | null | 2015-12-15 | BCG Intravesical | N | N | 10520401 | PACLITAXEL |
| 10004359 | 10002754 | 1.69 | 75 | Curative (C) | 2018-12-26 | 2018-12-30 | MaxiCHOP (Cycle 1) | N | N | 10520492 | PACLITAXEL |
| 10004360 | 10002755 | 1.58 | 66.2 | Curative (C) | 2015-10-25 | 2015-11-08 | Capecitabine 35days + RT | N | Y | 10520519 | CAPECITABINE + RT |
| 10004361 | 10002755 | 1.83 | 67 | Palliative (P) | 2015-04-17 | 2015-04-19 | Bortezomib +/- Dexamethasone | N | N | 10520519 | AZACITIDINE |
| 10004362 | 10002755 | 1.68 | 88.7 | Curative (C) | 2017-05-06 | 2017-05-22 | CYCLOPHOSPHAMIDE + THALIDOMIDE | N | Y | 10520519 | CHLORAMBUCIL |
| 10004363 | 10002756 | null | null | Disease modification (D) | 2017-08-03 | 2017-08-17 | Azacitidine | N | N | 10520720 | PACLITAXEL |
| 10004364 | 10002757 | 1.6 | 70.5 | Curative (C) | 2016-12-13 | 2017-05-16 | CISPLATIN + RT | 2 | Y | 10520743 | CISPLATIN + RT |
| 10004365 | 10002757 | 1.78 | 85 | Adjuvant (A) | 2016-08-10 | 2016-08-18 | Fluorouricil + Folonic Acid (MdG) | 2 | N | 10520743 | FLUOROURACIL |
| 10004366 | 10002757 | null | null | Palliative (P) | 2013-09-11 | 2013-09-11 | Cisplatin 7 day | N | N | 10520743 | CTD |
| 10004367 | 10002758 | 1.68 | 90.4 | Curative (C) | 2017-10-08 | 2017-10-08 | CTD | Y | N | 10520886 | BCG |
| 10004368 | 10002759 | 1.66 | null | Curative (C) | 2017-06-21 | 2017-07-11 | DABRAFENIB + TRAMETINIB | 01 | N | 10520923 | DOCETAXEL + NINTEDANIB |
| 10004369 | 10002760 | 1.62 | 60.7 | Palliative (P) | 2018-05-19 | 2018-05-19 | DABRAFENIB + TRAMETINIB | 02 | N | 10520930 | VISMODEGIB |
| 10004370 | 10002761 | 1.6 | 55.3 | Disease modification (D) | null | 2017-02-14 | TRASTUZUMAB | 01 | N | 10520949 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004371 | 10006633 | 0 | 91.6 | Not known (9) | 2017-03-07 | 2017-03-12 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 10520969 | CARBO + FLUOROURACIL |
| 10004372 | 10006633 | null | 114 | Disease modification (D) | 2017-12-13 | 2017-12-25 | Mitomycin Intravesical | 02 | N | 10520969 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10004373 | 10006633 | 1.76 | 63.9 | Palliative (P) | 2017-01-22 | 2017-02-16 | IPILIMUMAB + NIVOLUMAB | N | N | 10520969 | DABRAFENIB |
| 10004374 | 10002762 | 1.74 | 67.4 | Disease modification (D) | 2017-07-21 | 2017-07-23 | LENALIDOMIDE | N | N | 10521051 | MITOMYCIN INTRAVESICULAR |
| 10004375 | 10002763 | 1.77 | 60.5 | Palliative (P) | 2017-02-07 | 2017-02-17 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10521114 | OCTREOTIDE |
| 10004376 | 10006634 | 1.77 | 75.8 | Palliative (P) | 2016-02-24 | 2016-03-08 | Ofatumumab Monthly | N | N | 10521122 | CHLORAMBUCIL + RITUXIMAB |
| 10004377 | 10006634 | 0 | 99 | Disease modification (D) | 2013-10-13 | 2013-10-22 | Mitomycin Intravesical | N | N | 10521122 | CLADRIBINE |
| 10004378 | 10002764 | null | null | Palliative (P) | 2017-03-27 | 2017-03-27 | Mitomycin Intravesical | N | null | 10521449 | RIALTO TRIAL |
| 10004379 | 10002765 | 1.54 | 67.2 | Not known (9) | 2017-02-14 | 2017-03-26 | CARBOPLATIN + RT | N | Y | 10521499 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN |
| 10004380 | 10002766 | 1.72 | null | Not known (9) | 2017-08-12 | 2017-08-23 | CHLORAMBUCIL + RITUXIMAB | N | N | 10521521 | LENALIDOMIDE |
| 10004381 | 10002767 | 1.7 | 73.8 | Palliative (P) | 2017-10-28 | 2017-11-04 | Doxorubicin + Gemcitabine | 02 | null | 10521540 | BORTEZOMIB + THALIDOMIDE |
| 10004382 | 10002768 | 1.76 | 100 | Disease modification (D) | 2015-06-14 | 2015-06-15 | LENALIDOMIDE | Y | N | 10521566 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10004383 | 10002769 | null | null | Palliative (P) | 2017-07-11 | 2017-07-11 | Pemetrexed | N | null | 10521663 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10004384 | 10002770 | 1.72 | 85 | Disease modification (D) | 2014-04-05 | 2014-04-15 | Bendamustine +/- Prednisolone | N | N | 10521664 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10004385 | 10002771 | 1.77 | 60.6 | Disease modification (D) | 2017-10-30 | 2017-11-05 | RUXOLITINIB | 2 | N | 10521692 | CETUXIMAB + RT |
| 10004386 | 10006635 | 1.63 | 75.8 | Adjuvant (A) | 2015-05-29 | 2015-06-25 | Ipilimumab | 02 | N | 10521703 | BEVACIZUMAB + CAPECITABINE |
| 10004387 | 10008183 | 1.66 | 77.8 | Palliative (P) | 2014-12-12 | 2014-12-17 | CAPECITABINE + MITOMYCIN + RT | Y | N | 10521710 | FEC + DOCETAXEL + TRASTUZUMAB |
| 10004388 | 10008183 | 1.69 | 63.4 | Adjuvant (A) | 2015-12-23 | 2016-01-02 | CYCLOPHOSPHAMIDE + RITUXIMAB | 2 | N | 10521710 | RUXOLITINIB |
| 10004389 | 10008183 | 1.78 | 62.2 | Adjuvant (A) | 2016-12-20 | 2016-12-26 | IPILIMUMAB + NIVOLUMAB | 02 | N | 10521710 | MITOMYCIN INTRAVESICULAR |
| 10004390 | 10002772 | null | 68.8 | Curative (C) | 2015-08-26 | 2015-08-27 | METHOTREXATE | N | Y | 10521969 | GEFITINIB |
| 10004391 | 10002773 | null | 68.1 | Palliative (P) | 2017-07-15 | 2017-08-05 | VEPEMB | N | N | 10521975 | VEDEX |
| 10004392 | 10002774 | 1.77 | null | Curative (C) | 2018-08-12 | 2018-08-15 | CISPLATIN + FLUOROURACIL | N | Y | 10522024 | SCOPE 1 TRIAL |
| 10004393 | 10002775 | null | 62 | Curative (C) | 2017-01-30 | 2017-01-30 | Cyclophosphamide + Docetaxel | N | N | 10522135 | CAPECITABINE + CARBOPLATIN |
| 10004394 | 10002776 | 1.71 | null | Palliative (P) | 2017-03-11 | 2017-04-01 | Cyclophosphamide + Docetaxel | null | null | 10522146 | CISPLATIN + FLUOROURACIL + RT |
| 10004395 | 10002777 | null | null | Curative (C) | 2014-12-07 | 2014-12-10 | DA 3 + 10 | 02 | N | 10522302 | MITOMYCIN INTRAVESICULAR |
| 10004396 | 10002778 | 1.62 | 50 | Curative (C) | 2017-06-14 | 2017-06-16 | Ipilimumab | 02 | N | 10522325 | CAP + RT |
| 10004397 | 10002779 | 1.63 | 71.3 | Disease modification (D) | 2019-06-07 | 2019-07-05 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 2 | N | 10522430 | MELPHALAN |
| 10004398 | 10006636 | 1.61 | 65 | Disease modification (D) | 2015-09-20 | 2015-10-11 | DABRAFENIB + TRAMETINIB | N | N | 10522479 | MPV |
| 10004399 | 10006636 | 0 | 55.8 | Neo-adjuvant (N) | null | 2019-02-09 | STAMPEDE TRIAL | N | N | 10522479 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 10004400 | 10006636 | 1.72 | 83 | null | 2015-12-24 | 2015-12-24 | Mitomycin Intravesical | 2 | N | 10522479 | IRINOTECAN + MDG + PANITUMUMAB |
| 10004401 | 10002780 | 155 | 0 | Palliative (P) | 2017-03-13 | 2017-03-19 | DABRAFENIB + TRAMETINIB | N | N | 10522590 | VISMODEGIB |
| 10004402 | 10002781 | null | 48.299 | Palliative (P) | 2017-09-05 | 2017-09-10 | Ipilimumab | null | N | 10522682 | IDELALISIB + RITUXIMAB |
| 10004403 | 10002782 | 0 | 93.8 | Disease modification (D) | 2017-06-15 | 2017-07-26 | STAMPEDE TRIAL | N | N | 10522686 | CHLORAMBUCIL + RITUXIMAB |
| 10004404 | 10002783 | 1.63 | 77 | Curative (C) | 2015-10-27 | 2015-10-31 | Doxorubicin chemoembolisation | N | N | 10522696 | AML16 TRIAL |